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ABSTRACT
Fluticazone propionate (FP) is a new local corticosteroid which is twice as efficient than as beciometazole 
dipropionate with minimal oral biopresence following intranasal application. Its effect was studied in a total 
of 400 children aged 4-12 years monitored inlO of the geographic regions. The efficiency of the drug was as­
sessed by means of daily records registering the individual accompanying symptoms, nasal obstruction, 
choryza, sneezing, etc. Three groups of patients were investigated: 1) treated with lOOpg FP; 2) treated with 
20()pg FP and 3) placebo group. The results of the clinical study confirmed that 100 and 200pg FP adminis­
tered once daily suppressed all the typical symptoms of the seasonal allergic rhinitis in childhood.
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IN TRO D U CTIO N
Allergic rhinitis is a very common disease in early child­
hood which is, however, often misdiagnosed and mis­
treated. Surveys of the population have shown that its inci­
dence varies between 6-12% (1,5,9,10). In half of the chil­
dren the disease begins at the age of 2-4 years. Rhinitis is 
most common in boys aged 8-12 years. During childhood 
the incidence rate is steady and the condition seldom dies 
away without being treated (1). Complete recovery occurs 
in 10% only, 50% of the children show improvement, 30% 
remain unaffected and in 10% exacerbation is observed 
(11). Inspite of the fact that the condition is not life-threat­
ening, allergic rhinitis is accompanied by sneezing, 
choryza, nasal irritation and obstruction which may be­
come so severe that they may interfere with the normal 
daily activities and cause disturbances in the normal func­
tioning of the patients. When untreated, the nasal obstruc­
tion often causes complications such as dysfunction of the 
Eustachian tube, hearing damage and obstruction of the 
osteomeatallic complex with possible development of 
paranasal sinus infections.
It is known that the pathogenesis of allergic rhinitis is deter­
mined by the sequence of events at cellular level and re­
lease of other mediators apart from histamine which are 
manifested by nasal mucosa inflammation (8). Treatment 
should begin early to suppress inflammation and the devel­
opment of chronic nasal symptoms or other complications. 
The antiinflammatory drugs have proved their efficacy as a 
therapy in patients with rhinitis and the corticosteroids are
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highly efficient in suppressing the characteristic symptoms 
of the disease (8). The initial idea when applying local 
drugs stems from the desire to avoid the side effects typical 
of the systemically applied medicines. Besides, it has been 
proved that the local drug administration is important in its 
own self since the therapeutically equivalent dose does not 
necessarily help to achieve the same positive effect (7). At 
the same time, in children, the local corticosrtèroids are not 
considered an acceptable choice for treatment (8) because 
of the risk for side effects related to the suppression along 
the hypothalamus-pituitary-adrenal axis and for dysfunc­
tion of the bone metabolism with retarded growth (4).
The ideal corticosteroid for the treatment of allergic rhinitis 
in childhood should be a combination of pronounced local 
efficacy and low general activity. Fluticason propionate is a 
new local corticosteroid which is twice as powerful than 
beclometasone dipropionate with minimal oral biopresence 
following intranasal administration. Previous clinical trials 
with FP soluble nasal spray (FPNS) have shown that the 
drug has scarce general corticosteroid activity, it seems to 
be perfect for treatment o f allergic rhinitis in children (2). 
In order to assess the FPNS fficiency and the tolerance 
three randomised double-blind placebo-controlled clinical 
trials were undertaken in children with seasonal allergic 
rhinitis.
MATERIAL AND METHODS
A total o f400 children aged 4-12 were studied in 10 centres 
in Bulgaria All of them responded positively to the skin 
test to known seasonal allergens in the corresponding geo­
graphical region. The studies were conducted during the 
season in which the allergens were active. Besides, the cri­
teria included the symptoms chatacteristic of seasonal rhi- 
nitis, e.f nasal obstruction, choryza, eye irritation, etc. on
45
D. M arev
the day of examination. The requirement was that these 
symptoms had to be moderately severe during at least one 
of the previous seasons.
The clinical trial included 143 children with seasonal aller­
gic rhinitis, of whom 47 received 100 pg FPNS once a day, 
46 received 200 and 100 pg FPNS once a day and 50 - pla­
cebo, once daily in the morning. The patients were also 
given antihistamine tablets to suppress the symptoms left 
uncontrolled by the main treatment.
The efficiency of the applied treatment was evaluated by 
means of daily recording of the accompanying symptoms 
such as sneezing, choryza, nasal obstruction on awakening 
and during the day, nasal and eye irritation, etc. The pa­
tients also had to record the additional treatment received 
during tire day with antihistamine drugs (3).
The period of treatment was followed by a weak's period of 
monitoring. The patients were randomly selected for treat­
ment with FPNS in a dosage of lOOpg and 200pg, respec­
tively, and the third group received a placebo. All the 
groups were administered treatment once a day, in the 
morning. The patients had to record the severity of symp­
toms by means of the visual analogue scale (0=lack; 100 = 
severe fonn) for each of the symptoms. The efficiency was 
evaluated by medical specialists by means of the visual an­
alogue scale regarding the symptoms, and by the pa­
tients/parents regarding the severity of the nasal symptoms 
(nasal obstruction only ) in the morning and the severity of 
symptoms during the day. The overall effect of the admin­
istered treatment was given y the physicians at the end of 
each period of treatment
In all three trials the harenlessness of the treatment was de- 
tennined by the registered side effects on every visit. Be­
fore the beginning of active treatment and at its end hema­
tological, biochemical and urinary analyses were per­
forated.
RESULTS AND DISCUSSION
During the clinical trial the patients treated with FPNS of 
lOOpg and of 200pg once daily showed improvement in 
their average assessment of their nasal symptoms for each 
of die monitored symptoms which were significant as com­
pared to the placebo group. The only ecxception was that of 
nasal irritation which was significantly improved only in 
the group treated with FPNS of200pg once a day. Regard­
ing the improvement in the nasal symptoms assessment no 
significant difference was observed between the groups 
treated with 100 pg and 200pg once a day.
The watering and irritation of the eyes were not affected in 
the patients treated with 100 pg and 200pg FPNS as com­
pared to the placebo.
When comparing the patients treated with 100 pg FPNS 
with the placebo group, the additional administration of an­
tihistamine drugs was reduced significantly in the first 
group.
In comparison to the placebo group, the patients treated ac­
tively with lOOpg and 200pg FPNS once a day demon­
strated considerable improvement of their symptoms. No 
significant differences was established between the two 
groups of the actively treated patients.
In all three groups (placebo, 1 OOpg FPNS and 200pg FPNS 
once a day) no difference were observed in tire registered 
side effects. Tire reported side effects were usully mild and 
related to rhinitis. Treatement with flucticasone propionate 
did not influence tire morning level of serum cortisol and 
the 24-hour excretion of cortisol in urine.
CONCLUSION
The results of our trial confirm that FPNS lOOpg and 
200pg once a day has advantages over the placebo in sup­
pressing the symptoms characteristic of seasonal allergic 
rhinitis in childhood. The combination of powerful effect 
and low general activity of FPNS demonstrates the effi­
ciency of the drug in comparison with tire placebo and the 
advantage of low percentage of side effects in this age 
group. Axis in children treated with 1 OOpg and 200pg 
FPNS according to the results from the investigation of the 
morning levels of serum cortisol (6), or, when using more 
susceptible methods such as tire monitoring of tire 24-hour 
excretion of free cortisol in urine. Since bone metabolism is 
considered a more sensitive indicator of the general effect 
of the inhaled corticosteroids in comparison to tire changes 
in corticosol excretion with urine (4), it would be of interest 
to evaluate the effect of FP on bone metabolism. In a previ­
ous trial we have shown that a 2-month treatment with 
beclometazone dipropionate of 200 or 400pg daily does 
not affect bone metabolism in children with seasonal aller­
gic rhinitis.
FPNS of 1 OOpg daily would be an efficient and well-toler­
ated treatment in children with allergic rhinitis.
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